Alzheimer's disease (AD) is a neurodegenerative brain disorder associated with relentlessly progressive cognitive impairment and memory loss. AD pathology proceeds for decades before cognitive deficits become clinically apparent, opening a window for preventative therapy. Imbalance of clearance and buildup of amyloid β and phosphorylated tau proteins in the central nervous system is believed to contribute to AD pathogenesis. However, multiple clinical trials of treatments aimed at averting accumulation of these proteins have yielded little success, and there is still no disease-modifying intervention. Here, we discuss current knowledge of AD pathology and treatment with an emphasis on emerging biomarkers and treatment strategies.
DuX, WangX, GengM. Alzheimer's disease hypothesis and related therapies. Transl Neurodegener2018;7:2. doi:10.1186/s40035-018-0107-y
5.
LopezOL, KullerLH. Epidemiology of aging and associated cognitive disorders: prevalence and incidence of Alzheimer's disease and other dementias. Handb Clin Neurol2019;167:139–48.doi:10.1016/B978-0-12-804766-8.00009-1http://www.ncbi.nlm.nih.gov/pubmed/31753130
HardyJ. A hundred years of Alzheimer's disease research. Neuron2006;52:3–13.doi:10.1016/j.neuron.2006.09.016
8.
IngelssonM, FukumotoH, NewellKL, . Early A accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology2004;62:925–31.doi:10.1212/01.WNL.0000115115.98960.37
9.
VillemagneVL, BurnhamS, BourgeatP, . Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol2013;12:357–67.doi:10.1016/S1474-4422(13)70044-9http://www.ncbi.nlm.nih.gov/pubmed/23477989
PletnikovaO, KageyamaY, RudowG, . The spectrum of preclinical Alzheimer's disease pathology and its modulation by APOE genotype. Neurobiol Aging2018;71:72–80.doi:10.1016/j.neurobiolaging.2018.07.007
12.
WimoA, WinbladB, JönssonL. The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement2010;6:98–103.doi:10.1016/j.jalz.2010.01.010http://www.ncbi.nlm.nih.gov/pubmed/20298969
HardyJ, SelkoeDJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science2002;297:353–6.doi:10.1126/science.1072994http://www.ncbi.nlm.nih.gov/pubmed/12130773
18.
SelkoeDJ, HardyJ. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med2016;8:595–608.doi:10.15252/emmm.201606210
19.
PotterR, PattersonBW, ElbertDL, . Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers. Sci Transl Med2013;5:189ra77. doi:10.1126/scitranslmed.3005615
TolarM, AbushakraS, SabbaghM. The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis. Alzheimers Dement2020. doi:doi:10.1016/j.jalz.2019.09.075. [Epub ahead of print: 03 Jan 2020].http://www.ncbi.nlm.nih.gov/pubmed/31706733
HussainI, PowellD, HowlettDR, . Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci1999;14:419–27.doi:10.1006/mcne.1999.0811http://www.ncbi.nlm.nih.gov/pubmed/10656250
24.
Rivera-EscaleraF, PinneyJJ, OwlettL, . IL-1β-driven amyloid plaque clearance is associated with an expansion of transcriptionally reprogrammed microglia. J Neuroinflammation2019;16:261. doi:10.1186/s12974-019-1645-7http://www.ncbi.nlm.nih.gov/pubmed/31822279
25.
ChakrobortyS, KimJ, SchneiderC, . Early presynaptic and postsynaptic calcium signaling abnormalities mask underlying synaptic depression in presymptomatic Alzheimer's disease mice. J Neurosci2012;32:8341–53.doi:10.1523/JNEUROSCI.0936-12.2012
26.
DineleyKT, WestermanM, BuiD, . Beta-Amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci2001;21:4125–33.doi:10.1523/JNEUROSCI.21-12-04125.2001http://www.ncbi.nlm.nih.gov/pubmed/11404397
27.
RaddeR, BolmontT, KaeserSA, . Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep2006;7:940–6.doi:10.1038/sj.embor.7400784
28.
DrummondE, WisniewskiT. Alzheimer's disease: experimental models and reality. Acta Neuropathol2017;133:155–75.doi:10.1007/s00401-016-1662-x
29.
DevinskyO, BoeschJM, Cerda-GonzalezS, . A cross-species approach to disorders affecting brain and behaviour. Nat Rev Neurol2018;14:677–86.doi:10.1038/s41582-018-0074-z
30.
LemereCA, MaronR, SpoonerET, . Nasal Aβ treatment induces anti-Aβ antibody production and decreases cerebral amyloid burden in PD-APP mice. Ann N Y Acad Sci2000;920:328–31.doi:10.1111/j.1749-6632.2000.tb06943.x
31.
KingA. The search for better animal models of Alzheimer's disease. Nature2018;559:S13–15.doi:10.1038/d41586-018-05722-9
32.
JankowskyJL, ZhengH. Practical considerations for choosing a mouse model of Alzheimer's disease. Mol Neurodegener2017;12:89. doi:10.1186/s13024-017-0231-7
33.
GlennerGG, WongCW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun1984;120:885–90.doi:10.1016/S0006-291X(84)80190-4
34.
KosikKS, JoachimCL, SelkoeDJ. Microtubule-Associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A1986;83:4044–8.doi:10.1073/pnas.83.11.4044
35.
ThalDR, RübU, OrantesM, . Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology2002;58:1791–800.doi:10.1212/WNL.58.12.1791
36.
BraakH, AlafuzoffI, ArzbergerT, . Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol2006;112:389–404.doi:10.1007/s00401-006-0127-z
37.
MintunMA, LarossaGN, ShelineYI, . [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology2006;67:446–52.doi:10.1212/01.wnl.0000228230.26044.a4http://www.ncbi.nlm.nih.gov/pubmed/16894106
38.
BuchhaveP, MinthonL, ZetterbergH, . Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry2012;69:98–106.doi:10.1001/archgenpsychiatry.2011.155http://www.ncbi.nlm.nih.gov/pubmed/22213792
39.
SabriO, SabbaghMN, SeibylJ, . Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement2015;11:964–74.doi:10.1016/j.jalz.2015.02.004http://www.ncbi.nlm.nih.gov/pubmed/25824567
40.
CurtisC, GamezJE, SinghU, . Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. JAMA Neurol2015;72:287–94.doi:10.1001/jamaneurol.2014.4144
41.
ShepherdTM, NayakGK. Clinical use of integrated positron emission Tomography-Magnetic resonance imaging for dementia patients. Top Magn Reson Imaging2019;28:299–310.doi:10.1097/RMR.0000000000000225
42.
JagustW, ReedB, MungasD, . What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?Neurology2007;69:871–7.doi:10.1212/01.wnl.0000269790.05105.16
43.
FyfeI. Imaging shows predictive power of tau pathology in Alzheimer disease. Nat Rev Neurol2020;16:129. doi:10.1038/s41582-020-0326-6
44.
La JoieR, VisaniAV, BakerSL, . Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET. Sci Transl Med2020;12:eaau5732. doi:10.1126/scitranslmed.aau5732
45.
NelsonPT, AlafuzoffI, BigioEH, . Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol2012;71:362–81.doi:10.1097/NEN.0b013e31825018f7http://www.ncbi.nlm.nih.gov/pubmed/22487856
46.
LoweVJ, CurranG, FangP, . An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun2016;4:58.doi:10.1186/s40478-016-0315-6
47.
MeyerP-F, Pichet BinetteA, GonneaudJ, . Characterization of Alzheimer disease biomarker discrepancies using cerebrospinal fluid phosphorylated tau and AV1451 positron emission tomography. JAMA Neurol2020;77:508. doi:10.1001/jamaneurol.2019.4749
48.
MattssonN, SchöllM, StrandbergO, . 18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease. EMBO Mol Med2017;9:1212–23.doi:10.15252/emmm.201707809http://www.ncbi.nlm.nih.gov/pubmed/28743782
49.
TherriaultJ, BenedetAL, PascoalTA, . Association of apolipoprotein E ε4 with medial temporal tau independent of amyloid-β. JAMA Neurol2020;77:470–9.doi:10.1001/jamaneurol.2019.4421http://www.ncbi.nlm.nih.gov/pubmed/31860000
50.
JackCR, BennettDA, BlennowK, . NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement2018;14:535–62.doi:10.1016/j.jalz.2018.02.018http://www.ncbi.nlm.nih.gov/pubmed/29653606
51.
WippoldFJ, BrownDC, BroderickDF, . ACR appropriateness criteria dementia and movement disorders. J Am Coll Radiol2015;12:19–28.doi:10.1016/j.jacr.2014.09.025http://www.ncbi.nlm.nih.gov/pubmed/25557568
52.
KnopmanDS, DeKoskyST, CummingsJL, . Practice parameter: diagnosis of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology2001;56:1143–53.doi:10.1212/WNL.56.9.1143
53.
LombardiG, CrescioliG, CavedoE, . Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment. Cochrane Database Syst Rev2020;3:CD009628. doi:10.1002/14651858.CD009628.pub2http://www.ncbi.nlm.nih.gov/pubmed/32119112
54.
PiniL, PievaniM, BocchettaM, . Brain atrophy in Alzheimer's Disease and aging. Ageing Res Rev2016;30:25–48.doi:10.1016/j.arr.2016.01.002
55.
ApostolovaLG, GreenAE, BabakchanianS, . Hippocampal atrophy and ventricular enlargement in normal aging, mild cognitive impairment (MCI), and Alzheimer disease. Alzheimer Dis Assoc Disord2012;26:17–27.doi:10.1097/WAD.0b013e3182163b62http://www.ncbi.nlm.nih.gov/pubmed/22343374
56.
RusinekH, De SantiS, FridD, . Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology2003;229:691–6.doi:10.1148/radiol.2293021299http://www.ncbi.nlm.nih.gov/pubmed/14657306
57.
FrisoniGB, BocchettaM, ChételatG, . Imaging markers for Alzheimer disease: which vs how. Neurology2013;81:487–500.doi:10.1212/WNL.0b013e31829d86e8
58.
JangH, ParkJ, WooS, . Prediction of fast decline in amyloid positive mild cognitive impairment patients using multimodal biomarkers. Neuroimage2019;24:101941. doi:10.1016/j.nicl.2019.101941
59.
ImbimboBP, WatlingM. Investigational BACE inhibitors for the treatment of Alzheimer's disease. Expert Opin Investig Drugs2019;28:967–75.doi:10.1080/13543784.2019.1683160
60.
JoeE, RingmanJM. Cognitive symptoms of Alzheimer's disease: clinical management and prevention. BMJ2019;367:l6217. doi:10.1136/bmj.l6217http://www.ncbi.nlm.nih.gov/pubmed/31810978
61.
KabirMT, UddinMS, BegumMM, . Cholinesterase inhibitors for Alzheimer's disease: multitargeting strategy based on anti-Alzheimer's drugs repositioning. Curr Pharm Des2019;25:3519–35.doi:10.2174/1381612825666191008103141http://www.ncbi.nlm.nih.gov/pubmed/31593530
62.
Darreh-ShoriT, SoininenH. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies. Curr Alzheimer Res2010;7:67–73.doi:10.2174/156720510790274455
63.
SzetoJ.Y.Y., LewisS.J.G.. Current treatment options for Alzheimer's disease and Parkinson's disease dementia. Curr Neuropharmacol2016;14:326–38.doi:10.2174/1570159X14666151208112754
64.
ArvanitakisZ, ShahRC, BennettDA. Diagnosis and management of dementia: review. JAMA2019;322:1589–99.doi:10.1001/jama.2019.4782
65.
BondM, RogersG, PetersJ, . The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of technology appraisal No. 111): a systematic review and economic model. Health Technol Assess2012;16:1–470.doi:10.3310/hta16210http://www.ncbi.nlm.nih.gov/pubmed/22541366
66.
KnightR, KhondokerM, MagillN, . A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia. Dement Geriatr Cogn Disord2018;45:131–51.doi:10.1159/000486546
CuiC-C, SunY, WangX-Y, . The effect of anti-dementia drugs on Alzheimer disease-induced cognitive impairment. Medicine2019;98:e16091. doi:10.1097/MD.0000000000016091
69.
GlinzD, GloyVL, MonschAU, . Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis. Swiss Med Wkly2019;149:w20093. doi:10.4414/smw.2019.20093http://www.ncbi.nlm.nih.gov/pubmed/31269225
70.
LaverK, DyerS, WhiteheadC, . Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews. BMJ Open2016;6:e010767. doi:10.1136/bmjopen-2015-010767http://www.ncbi.nlm.nih.gov/pubmed/27121704
71.
BrasureM, DesaiP, DavilaH, . Physical activity interventions in preventing cognitive decline and Alzheimer-type dementia. Ann Intern Med2018;168:30–8.doi:10.7326/M17-1528
72.
ChengG, HuangC, DengH, . Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J2012;42:484–91.doi:10.1111/j.1445-5994.2012.02758.x
73.
MarioniRE, Proust-LimaC, AmievaH, . Social activity, cognitive decline and dementia risk: a 20-year prospective cohort study. BMC Public Health2015;15:1089. doi:10.1186/s12889-015-2426-6
74.
LiX-Y, ZhangM, XuW, . Midlife modifiable risk factors for dementia: a systematic review and meta-analysis of 34 prospective cohort studies. Curr Alzheimer Res2019;16:1254–68.doi:10.2174/1567205017666200103111253http://www.ncbi.nlm.nih.gov/pubmed/31902364
75.
BattyGD, ShipleyMJ, KvaavikE, . Biomarker assessment of tobacco smoking exposure and risk of dementia death: pooling of individual participant data from 14 cohort studies. J Epidemiol Community Health2018;72:513–5.doi:10.1136/jech-2017-209922
76.
KimJW, LeeDY, LeeBC, . Alcohol and cognition in the elderly: a review. Psychiatry Investig2012;9:8–16.doi:10.4306/pi.2012.9.1.8
77.
PolancoJC, LiC, BodeaL-G, . Amyloid-β and tau complexity - towards improved biomarkers and targeted therapies. Nat Rev Neurol2018;14:22–39.doi:10.1038/nrneurol.2017.162http://www.ncbi.nlm.nih.gov/pubmed/29242522
78.
MullaneK, WilliamsM. Preclinical models of Alzheimer's disease: relevance and translational validity. Curr Protoc Pharmacol2019;84:e57. doi:10.1002/cpph.57
79.
HuangL-K, ChaoS-P, HuC-J. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci2020;27:18. doi:10.1186/s12929-019-0609-7
80.
DoggrellSA. Lessons that can be learnt from the failure of verubecestat in Alzheimer's disease. Expert Opin Pharmacother2019;20:2095–9.doi:10.1080/14656566.2019.1654998
81.
TripathiM, TripathiM, ParidaG, . Biomarker-Based prediction of progression to dementia: F-18 FDG-PET in amnestic MCI. Neurol India2019;67:1310–7.doi:10.4103/0028-3886.271245
82.
GuptaY, LamaRK, KwonG-R, . Prediction and classification of Alzheimer's disease based on combined features from apolipoprotein-E genotype, cerebrospinal fluid, Mr, and FDG-PET imaging biomarkers. Front Comput Neurosci2019;13:72. doi:10.3389/fncom.2019.00072http://www.ncbi.nlm.nih.gov/pubmed/31680923
83.
BawaKK, KranceSH, HerrmannN, . A peripheral neutrophil-related inflammatory factor predicts a decline in executive function in mild Alzheimer's disease. J Neuroinflammation2020;17:84. doi:10.1186/s12974-020-01750-3
84.
GuanJ, WangP, LuL, . Association of Plasma Transferrin With Cognitive Decline in Patients With Mild Cognitive Impairment and Alzheimer's Disease. Front Aging Neurosci2020;12:38. doi:10.3389/fnagi.2020.00038
85.
FrisoniGB, BoccardiM, BarkhofF, . Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurol2017;16:661–76.doi:10.1016/S1474-4422(17)30159-Xhttp://www.ncbi.nlm.nih.gov/pubmed/28721928
86.
MattssonN, LönneborgA, BoccardiM, . Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging2017;52:196–213.doi:10.1016/j.neurobiolaging.2016.02.034http://www.ncbi.nlm.nih.gov/pubmed/28317649
87.
SantangeloR, Dell'EderaA, SalaA, . The CSF p-tau181/Aβ42 Ratio Offers a Good Accuracy “In Vivo” in the Differential Diagnosis of Alzheimer's Dementia. Curr Alzheimer Res2019;16:587–95.doi:10.2174/1567205016666190725150836
88.
JanelidzeS, StomrudE, SmithR, . Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. Nat Commun2020;11:1683. doi:10.1038/s41467-020-15436-0
89.
TakousisP, SadlonA, SchulzJ, . Differential expression of microRNAs in Alzheimer's disease brain, blood, and cerebrospinal fluid. Alzheimers Dement2019;15:1468–77.doi:10.1016/j.jalz.2019.06.4952http://www.ncbi.nlm.nih.gov/pubmed/31495604
90.
Herrera-EspejoS, Santos-ZorrozuaB, Álvarez-GonzálezP, . A systematic review of microRNA expression as biomarker of late-onset Alzheimer's disease. Mol Neurobiol2019;56:8376–91.doi:10.1007/s12035-019-01676-9http://www.ncbi.nlm.nih.gov/pubmed/31240600
91.
YangQ, ZhaoQ, YinY. miR-133B is a potential diagnostic biomarker for Alzheimer's disease and has a neuroprotective role. Exp Ther Med2019;18:2711–8.doi:10.3892/etm.2019.7855http://www.ncbi.nlm.nih.gov/pubmed/31572518
92.
KennyA, McArdleH, CaleroM, . Elevated plasma microRNA-206 levels predict cognitive decline and progression to dementia from mild cognitive impairment. Biomolecules2019;9:E734. doi:10.3390/biom9110734
93.
CaoF, LiuZ, SunG. Diagnostic value of miR-193a-3p in Alzheimer's disease and miR-193a-3p attenuates amyloid-β induced neurotoxicity by targeting PTEN. Exp Gerontol2020;130:110814. doi:10.1016/j.exger.2019.110814
94.
DehghaniR, RahmaniF, RezaeiN. Microrna in Alzheimer's disease revisited: implications for major neuropathological mechanisms. Rev Neurosci2018;29:161–82.doi:10.1515/revneuro-2017-0042http://www.ncbi.nlm.nih.gov/pubmed/28941357
95.
D'AncaM, FenoglioC, SerpenteM, . Exosome determinants of physiological aging and age-related neurodegenerative diseases. Front Aging Neurosci2019;11:232. doi:10.3389/fnagi.2019.00232http://www.ncbi.nlm.nih.gov/pubmed/31555123
96.
SzepesiZ, ManouchehrianO, BachillerS, . Bidirectional Microglia-Neuron communication in health and disease. Front Cell Neurosci2018;12:323. doi:10.3389/fncel.2018.00323http://www.ncbi.nlm.nih.gov/pubmed/30319362
97.
MathewsPM, LevyE. Exosome production is key to neuronal endosomal pathway integrity in neurodegenerative diseases. Front Neurosci2019;13:1347. doi:10.3389/fnins.2019.01347http://www.ncbi.nlm.nih.gov/pubmed/31911768
98.
MaloneER, OlivaM, SabatiniPJB, . Molecular profiling for precision cancer therapies. Genome Med2020;12:8. doi:10.1186/s13073-019-0703-1http://www.ncbi.nlm.nih.gov/pubmed/31937368
PampuscenkoK, MorkunieneR, SneiderisT, . Extracellular tau induces microglial phagocytosis of living neurons in cell cultures. J Neurochem2019:e14940. doi:10.1111/jnc.14940http://www.ncbi.nlm.nih.gov/pubmed/31834946
102.
TannenbergRK, ScottHL, WestphalenRI, . The identification and characterization of excitotoxic nerve-endings in Alzheimer disease. Curr Alzheimer Res2004;1:11–25.doi:10.2174/1567205043480591http://www.ncbi.nlm.nih.gov/pubmed/15975081
103.
ShinoharaM, TachibanaM, KanekiyoT, . Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies. J Lipid Res2017;58:1267–81.doi:10.1194/jlr. R075796http://www.ncbi.nlm.nih.gov/pubmed/28381441
104.
de la MonteSM. Type 3 diabetes is sporadic Alzheimer's disease: mini-review. Eur Neuropsychopharmacol2014;24:1954–60.doi:10.1016/j.euroneuro.2014.06.008http://www.ncbi.nlm.nih.gov/pubmed/25088942
105.
AljanabiNM, MamtaniS, Al-GhuraibawiMMH, . Alzheimer's and hyperglycemia: role of the insulin signaling pathway and GSK-3 inhibition in paving a path to dementia. Cureus2020;12:e6885. doi:10.7759/cureus.6885http://www.ncbi.nlm.nih.gov/pubmed/32190448
106.
DubeySK, LakshmiKK, KrishnaKV, . Insulin mediated novel therapies for the treatment of Alzheimer's disease. Life Sci2020;249:117540. doi:10.1016/j.lfs.2020.117540http://www.ncbi.nlm.nih.gov/pubmed/32165212
107.
ReissAB, VoloshynaI. Regulation of cerebral cholesterol metabolism in Alzheimer disease. J Investig Med2012;60:576–82.doi:10.2310/JIM.0b013e318246d973http://www.ncbi.nlm.nih.gov/pubmed/22367100
YoshidaK, MoeinA, BittnerT, . Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer's disease. Alzheimers Res Ther2020;12:16.doi:10.1186/s13195-020-0580-2
110.
SallowayS, SperlingR, FoxNC, . Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med2014;370:322–33.doi:10.1056/NEJMoa1304839
111.
DoodyRS, ThomasRG, FarlowM, . Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med2014;370:311–21.doi:10.1056/NEJMoa1312889
112.
ServickK. Another major drug candidate targeting the brain plaques of Alzheimer's disease has failed. What's left?Science2019. [Epub ahead of print: 21 Mar 2019].
113.
HenleyD, RaghavanN, SperlingR, . Preliminary results of a trial of atabecestat in preclinical Alzheimer's Disease. N Engl J Med2019;380:1483–5.doi:10.1056/NEJMc1813435
114.
WesselsAM, TariotPN, ZimmerJA, . Efficacy and safety of Lanabecestat for treatment of early and mild Alzheimer disease: the amaranth and DAYBREAK-ALZ randomized clinical trials. JAMA Neurol2019;77:199–209.doi:10.1001/jamaneurol.2019.3988http://www.ncbi.nlm.nih.gov/pubmed/31764959
115.
DoodyRS, RamanR, FarlowM, . A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med2013;369:341–50.doi:10.1056/NEJMoa1210951http://www.ncbi.nlm.nih.gov/pubmed/23883379
